Business Description
Dynavax Technologies Corp
NAICS : 325412
SIC : 2834
ISIN : US2681582019
Share Class Description:
FRA:DYF1: Ordinary SharesDescription
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.93 | |||||
| Equity-to-Asset | 0.63 | |||||
| Debt-to-Equity | 0.39 | |||||
| Debt-to-EBITDA | 7.58 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.55 | |||||
| Beneish M-Score | -1.97 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 57.8 | |||||
| 3-Year Book Growth Rate | 108.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 178.52 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 18.91 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 73.5 | |||||
| 9-Day RSI | 70.03 | |||||
| 14-Day RSI | 66.63 | |||||
| 6-1 Month Momentum % | -7.44 | |||||
| 12-1 Month Momentum % | -20.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.18 | |||||
| Quick Ratio | 13.18 | |||||
| Cash Ratio | 11.83 | |||||
| Days Inventory | 455.64 | |||||
| Days Sales Outstanding | 69 | |||||
| Days Payable | 30.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.5 | |||||
| Shareholder Yield % | 0.23 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 82.03 | |||||
| Operating Margin % | -6.79 | |||||
| Net Margin % | 6.88 | |||||
| FCF Margin % | 14.3 | |||||
| ROE % | 2.8 | |||||
| ROA % | 1.75 | |||||
| ROIC % | -7.48 | |||||
| 3-Year ROIIC % | 110.27 | |||||
| ROC (Joel Greenblatt) % | 19.46 | |||||
| ROCE % | 2.73 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 109.27 | |||||
| Forward PE Ratio | 33.36 | |||||
| PE Ratio without NRI | 114.48 | |||||
| PS Ratio | 6.87 | |||||
| PB Ratio | 2.45 | |||||
| Price-to-Tangible-Book | 2.46 | |||||
| Price-to-Free-Cash-Flow | 53.9 | |||||
| Price-to-Operating-Cash-Flow | 48.27 | |||||
| EV-to-EBIT | 43.08 | |||||
| EV-to-EBITDA | 32.98 | |||||
| EV-to-Revenue | 4.37 | |||||
| EV-to-Forward-Revenue | 3.47 | |||||
| EV-to-FCF | 30.86 | |||||
| Price-to-Projected-FCF | 2.39 | |||||
| Price-to-Median-PS-Value | 0.36 | |||||
| Price-to-Graham-Number | 3.54 | |||||
| Price-to-Net-Current-Asset-Value | 3.1 | |||||
| Price-to-Net-Cash | 4.36 | |||||
| Earnings Yield (Greenblatt) % | 2.32 | |||||
| FCF Yield % | 2.24 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dynavax Technologies Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 231.4 | ||
| EPS (TTM) (€) | 0.104 | ||
| Beta | 0.29 | ||
| Volatility % | 21.34 | ||
| 14-Day RSI | 66.63 | ||
| 14-Day ATR (€) | 0.265595 | ||
| 20-Day SMA (€) | 10.11745 | ||
| 12-1 Month Momentum % | -20.6 | ||
| 52-Week Range (€) | 8.6 - 13.45 | ||
| Shares Outstanding (Mil) | 131.04 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dynavax Technologies Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dynavax Technologies Corp Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Dynavax Technologies Corp Frequently Asked Questions
What is Dynavax Technologies Corp(FRA:DYF1)'s stock price today?
The current price of FRA:DYF1 is €11.21. The 52 week high of FRA:DYF1 is €13.45 and 52 week low is €8.60.
When is next earnings date of Dynavax Technologies Corp(FRA:DYF1)?
The next earnings date of Dynavax Technologies Corp(FRA:DYF1) is 2025-02-21 Est..
Does Dynavax Technologies Corp(FRA:DYF1) pay dividends? If so, how much?
Dynavax Technologies Corp(FRA:DYF1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers